All In MedTech

Device Trial Radar · NCT06716580

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Sep 1, 2027

Study completion Sep 1, 2030

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beth Israel Deaconess Medical Center; Boston Medical Center; Massachusetts General Hospital
First posted
Dec 4, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Conditions

  • Lung Cancer
  • EGFR Gene Mutation

Interventions

  • Circulating Tumor DNA (ctDNA) AssayDevice

    Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection Rate of Non-Small Cell Lung CancerTime frame: 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.